Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Loxo Oncology
Pharma
SABCS: Lilly aims at broader adjuvant breast cancer nod
With longer-term data, Lilly hopes to convince the FDA to remove a biomarker restriction on Verzenio's post-surgery HR+/HER2- breast cancer use.
Angus Liu
Dec 6, 2022 3:00pm
Eli Lilly's Retevmo gets FDA nod to treat all RET cancer types
Sep 22, 2022 11:15am
AZ new head of diagnostic strategy drives biomarker awareness
Apr 26, 2021 10:34am
Lilly wins FDA nod for first-in-class cancer drug Retevmo
May 11, 2020 11:26am
How Merck's desire for more 'control' became a $2.7B ArQule buy
Dec 19, 2019 11:56am
How one hot protein family is driving cancer drug deals: report
Aug 21, 2019 11:55am
